{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:38:58Z","timestamp":1790419138847,"version":"4.1.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI18\/01366"],"award-info":[{"award-number":["PI18\/01366"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI19\/00588"],"award-info":[{"award-number":["PI19\/00588"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI19\/00815"],"award-info":[{"award-number":["PI19\/00815"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI21\/00251"],"award-info":[{"award-number":["PI21\/00251"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI20\/00744"],"award-info":[{"award-number":["PI20\/00744"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0001"],"award-info":[{"award-number":["RD21\/0005\/0001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for &amp;gt;50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and\/or CKD. The cardiorenal benefits\u2014on a relative scale\u2014appear similar in patients with or without diabetes. Specialty societies\u2019 guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.<\/jats:p>","DOI":"10.1093\/ndt\/gfad112","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T23:26:37Z","timestamp":1685057197000},"page":"2444-2455","source":"Crossref","is-referenced-by-count":61,"title":["SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA"],"prefix":"10.1093","volume":"38","author":[{"given":"Patrick B","family":"Mark","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki , Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ekart","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Maribor , Taborska 8, Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J","family":"Ferro","sequence":"additional","affiliation":[{"name":"Renal Unit, University Hospitals Birmingham and Institute of Cardiovascular Science, University of Birmingham , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Balafa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital of Ioannina , Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fernandez-Fernandez","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Universidad Aut\u00f3noma Madrid . Spain , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Herrington","sequence":"additional","affiliation":[{"name":"Medical Research Council Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM CIC-P 1433, CHRU de Nancy, INSERM U1116, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy , France"},{"name":"Service de Sp\u00e9cialit\u00e9s M\u00e9dicales et de N\u00e9phrologie-H\u00e9modialyse Centre Hospitalier Princesse Grace de Monaco , Monaco, Monaco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, ASST Lecco , Lecco , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Valdivielso","sequence":"additional","affiliation":[{"name":"Vascular and Renal Translational Research Group and UDETMA, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[{"name":"CNR-IFC, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension , Reggio Calabria , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Universidad Aut\u00f3noma Madrid . Spain , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionut","family":"Nistor","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy \u2018Grigore T. Popa\u2019 , Ia\u0219i , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"2023103100564683200_bib1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib2","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103100564683200_bib3","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition.","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2023103100564683200_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib6","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2023103100564683200_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/gfab167","article-title":"Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease","volume":"38","author":"Ortiz","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ajh.2008.206","article-title":"Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis","volume":"21","author":"Sarafidis","year":"2008","journal-title":"Am J Hypertens"},{"key":"2023103100564683200_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib10","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"2023103100564683200_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(16)30508-6","article-title":"The heart and vascular system in dialysis","volume":"388","author":"Wanner","year":"2016","journal-title":"Lancet"},{"key":"2023103100564683200_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2023103100564683200_bib13","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20132010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2023103100564683200_bib16","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1681\/ASN.2019010064","article-title":"Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS Program","volume":"30","author":"Neuen","year":"2019","journal-title":"JASN"},{"key":"2023103100564683200_bib17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib18","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib19","doi-asserted-by":"crossref","first-page":"101163","DOI":"10.1016\/j.eclinm.2021.101163","article-title":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials","volume":"41","author":"Staplin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2023103100564683200_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol Rev"},{"key":"2023103100564683200_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2023103100564683200_bib23","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023103100564683200_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023103100564683200_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2023103100564683200_bib26","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023103100564683200_bib27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"2023103100564683200_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"2023103100564683200_bib29","doi-asserted-by":"crossref","first-page":"e98720","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"2023103100564683200_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000506534","article-title":"Mitigation of the adverse consequences of nutrient excess on the kidney: a unified hypothesis to explain the renoprotective effects of sodium-glucose cotransporter 2 inhibitors","volume":"51","author":"Packer","year":"2020","journal-title":"Am J Nephrol"},{"key":"2023103100564683200_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/a-0958-2441","article-title":"Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes","volume":"51","author":"Wu","year":"2019","journal-title":"Horm Metab Res"},{"key":"2023103100564683200_bib32","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection","volume":"8","author":"Umino","year":"2018","journal-title":"Sci Rep"},{"key":"2023103100564683200_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13098-019-0454-6","article-title":"Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice","volume":"11","author":"Inoue","year":"2019","journal-title":"Diabetol Metab Syndr"},{"key":"2023103100564683200_bib34","doi-asserted-by":"crossref","first-page":"e129034","DOI":"10.1172\/jci.insight.129034","article-title":"Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"2023103100564683200_bib35","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib36","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023103100564683200_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"2023103100564683200_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2023103100564683200_bib40","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial","volume":"37","author":"Wheeler","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1159\/000519812","article-title":"The therapeutic evaluation of steroids in IgA Nephropathy Global (TESTING) Study: trial design and baseline characteristics","volume":"52","author":"Wong","year":"2021","journal-title":"Am J Nephrol"},{"key":"2023103100564683200_bib42","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING Randomized Clinical Trial","volume":"318","author":"Lv","year":"2017","journal-title":"J Am Med Assoc"},{"key":"2023103100564683200_bib43","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet North Am Ed"},{"key":"2023103100564683200_bib44","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib45","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2023103100564683200_bib46","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/ndt\/gfaa329","article-title":"SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, \u2018diabetic nephropathy\u2019, IgA nephropathy and podocytopathies with FSGS lesions","volume":"37","author":"Anders","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","article-title":"SGLT-2 inhibition in IgA nephropathy: the new standard of care?","volume":"100","author":"Barratt","year":"2021","journal-title":"Kidney Int"},{"key":"2023103100564683200_bib48","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib49","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2023103100564683200_bib53","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib54","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ckj\/sfac146","article-title":"Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients","volume":"15","author":"Mark","year":"2022","journal-title":"Clin Kidney J"},{"key":"2023103100564683200_bib55","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023103100564683200_bib56","first-page":"117","article-title":"The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C et al. Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2022","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","author":"Group","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib59","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib60","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023103100564683200_bib61","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023103100564683200_bib62","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY Analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2023103100564683200_bib63","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2023103100564683200_bib64","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2023103100564683200_bib65","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: eMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023103100564683200_bib66","first-page":"254","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC: Heart Failure"},{"key":"2023103100564683200_bib67","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023103100564683200_bib68","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jcjd.2017.11.004","article-title":"Chronic kidney disease in diabetes","volume":"42","author":"McFarlane","year":"2018","journal-title":"Can J Diabetes"},{"key":"2023103100564683200_bib69","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2023103100564683200_bib70","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2023103100564683200_bib71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"2023103100564683200_bib72","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023103100564683200_bib73","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","article-title":"Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR &lt;45\u00a0mL\/min)","volume":"30","author":"ERBP","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib74","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100564683200_bib75","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"2023103100564683200_bib76","doi-asserted-by":"crossref","first-page":"o775","DOI":"10.1136\/bmj.o775","article-title":"Type 2 diabetes: summary of updated NICE guidance","volume":"377","author":"Moran","year":"2022","journal-title":"BMJ"},{"key":"2023103100564683200_bib77"},{"key":"2023103100564683200_bib78","year":"2022"},{"key":"2023103100564683200_bib79","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MNH.0000000000000786","article-title":"Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy?","volume":"31","author":"McQuarrie","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2023103100564683200_bib80","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in Type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad112\/50703574\/gfad112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/11\/2444\/52661094\/gfad112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/11\/2444\/52661094\/gfad112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:27:50Z","timestamp":1698719270000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/11\/2444\/7180009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":80,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad112","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,25]]}}}